Literature DB >> 16093456

Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy.

Y-W Chen1, K Nagaraju, M Bakay, O McIntyre, R Rawat, R Shi, E P Hoffman.   

Abstract

OBJECTIVE: To identify stage-specific induction of molecular pathology pathways in Duchenne muscular dystrophy (DMD).
METHODS: We performed mRNA profiling using muscles from fetopsies, infants (aged 8 to 10 months), and symptomatic patients (aged 5 to 12 years) with DMD, and age- and sex-matched controls. We performed immunohistochemistry to determine changes at the protein level and protein localization.
RESULTS: Activated tissue dendritic cells, expression of toll-like receptor 7, and strong induction of nuclear factor-kappaB pathways occurred soon after birth in DMD muscle. Two muscle wasting pathways, atrogin-1 and myostatin, were not induced at any stage of the disease. Normal muscle showed accumulation of glycolytic and oxidative metabolism capacity with increased age, but this accumulation failed in DMD. The transforming growth factor (TGF)-beta pathway was strongly induced in symptomatic patients, with expression of TGFbeta type II receptor and apoptosis signal-regulating kinase 1 proteins on subsets of mature DMD myofibers.
CONCLUSIONS: Our data show stage-specific remodeling of human dystrophin-deficient muscle, with inflammatory pathways predominating in the presymptomatic stages and acute activation of TGFbeta and failure of metabolic pathways later in the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093456     DOI: 10.1212/01.wnl.0000173836.09176.c4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  147 in total

1.  Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys.

Authors:  Utkarsh J Dang; Michael Ziemba; Paula R Clemens; Yetrib Hathout; Laurie S Conklin; Eric P Hoffman
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

2.  Sparing of extraocular muscle in aging and muscular dystrophies: a myogenic precursor cell hypothesis.

Authors:  Kristen M Kallestad; Sadie L Hebert; Abby A McDonald; Mark L Daniel; Sharon R Cu; Linda K McLoon
Journal:  Exp Cell Res       Date:  2011-01-27       Impact factor: 3.905

3.  Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.

Authors:  D M Escolar; A Zimmerman; T Bertorini; P R Clemens; A M Connolly; L Mesa; K Gorni; A Kornberg; H Kolski; N Kuntz; Y Nevo; C Tesi-Rocha; K Nagaraju; S Rayavarapu; L P Hache; J E Mayhew; J Florence; F Hu; A Arrieta; E Henricson; R T Leshner; J K Mah
Journal:  Neurology       Date:  2012-03-07       Impact factor: 9.910

4.  Maternal obesity induces fibrosis in fetal myocardium of sheep.

Authors:  Yan Huang; Xu Yan; Jun X Zhao; Mei J Zhu; Richard J McCormick; Stephen P Ford; Peter W Nathanielsz; Jun Ren; Min Du
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-09-28       Impact factor: 4.310

5.  Computational Analysis of Muscular Dystrophy Sub-types Using A Novel Integrative Scheme.

Authors:  Chen Wang; Sook Ha; Jianhua Xuan; Yue Wang; Eric Hoffman
Journal:  Neurocomputing       Date:  2012-09-01       Impact factor: 5.719

6.  Translating mighty mice into neuromuscular therapeutics: is bigger muscle better?

Authors:  Eric P Hoffman; Diana Escolar
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

7.  Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy.

Authors:  Stephanie A Parsons; Douglas P Millay; Michelle A Sargent; Elizabeth M McNally; Jeffery D Molkentin
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

8.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 9.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

10.  Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle.

Authors:  Erik P Rader; Rolf Turk; Tobias Willer; Daniel Beltrán; Kei-Ichiro Inamori; Taylor A Peterson; Jeffrey Engle; Sally Prouty; Kiichiro Matsumura; Fumiaki Saito; Mary E Anderson; Kevin P Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.